Voyager Therapeutics, Inc.
VYGR
$3.46
$0.10423.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -229.18% | -173.80% | -161.15% | 65.08% | 54.34% |
| Total Depreciation and Amortization | -23.49% | -15.22% | -24.27% | 19.79% | 28.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.67% | 42.35% | 75.43% | 43.49% | 117.06% |
| Change in Net Operating Assets | 80.93% | -117.86% | 120.16% | -868.03% | -264.09% |
| Cash from Operations | -5.32% | -164.48% | 38.85% | -32.86% | -3,682.04% |
| Capital Expenditure | -14.27% | 69.27% | 79.47% | 67.01% | 20.08% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.69% | 144.57% | -198.04% | 141.02% | -49.13% |
| Cash from Investing | 105.38% | 142.89% | -201.38% | 140.65% | -45.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -10.16% | -99.93% | 24.78% | -95.77% | -63.11% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -10.16% | -99.93% | 24.78% | -95.77% | -63.11% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.97% | -95.52% | -1,264.96% | 120.33% | -179.55% |